We needn't concern ourselves with the gap opened on 25 April as today it closed. Those pesky gaps from release of videos from Australia, they close 91% of the time. As we head into the week, the low point was today and it's all anticipation of good things to come going forward.
Every long's best dreams are realized, in the days following news agencies recount a record number of bankruptcies being filed by (crooks) short sellers, and the reported closure of several sleazy hedge funds is rumored. Wall Street goes into shock envy, CNBC talking heads go wild, AF's alleged connections to organized crimes in short attacks are exposed by the SEC, he is picked up by the FBI. While handcuffed, is heard on live camera saying "No comment" to all the hurried questions of reporters. Agents roughly push his head below the clearance of the FBI's black unmarked sedan back seat as they slam the door on him. Reporters are going berserk, recounting what they've heard as to the dark deeds of this apparent lowlife, as the sedan speeds off. Cramer is heard saying that afternoon on Mad Money that he barely knew the man.
9users liked this postsusers disliked this posts0Reply
Facts about upcoming IDMC meeting
by hbrotha13 • Apr 2, 2016 8:28 AM Flag
The IDMC review of the will not be released per IDMC guidelines, unless the study is halted for efficacy. The IDMC will see the data, of course, but Galena will not (at least, they aren't supposed to) and none of the actual p values or other statistical information regarding efficacy will be released to the public, and it shouldn't be - if the company were to be unblinded to the data that would come at an expense of alpha.
So between now and June, The IDMC will make a determination (GTC, HFE, HFF), and that is the only information that will be released outside of that meeting. The idea that at some point anytime soon we are definitively going to see the efficacy of Neuvax is FALSE. You would only have to listen to the CMO to know this.
From the Q4 conference call - Dr. Bijan Nejadnik
"It is important to note that the study is double-blind, which means the physicians, the study staff, the company, the patients and all people working on the trial are unaware of whether a patient is receiving is NeuVax or placebo. The EAC is also blinded to the treatment of site. The IDMC is the only committee that will receive information on each patient's treatment assignment...Let me remind you this is not an efficacy analysis, once the 70 qualifying events are confirmed by the EAC the clinical data is compiled and submitted to the IDMC. The IDMC then needs to evaluate the data package for safety and futility. To reiterate what marks there earlier, regardless of the timing of the 70th event, we expect the IDMC review to be completed and the result of interim analysis to be announced by the end of June." Less
Interim IDMC recommendation to FDA doesn't unblinded data since the trial still has 2 more years, so I've come to understand. Where do you differ, source?
Did you get out of STEM finally, if not the shares did rally this past month from their lows in the 22 cent range. They garnered some attention finally for their stem cell product.
Thanks George, nice to have the links all in one post. Investor's may forget what they read, but what they watch as proof of concept and emerging efficacy in real people regaining their faculties and personalities, with complex motor skills returning, that isn't easily forgotten when we get attacked by the dark side.
Never have I heard nor would I think that is the primary motivation behind a cash raise. They must have an agenda that is timely and opportune, but we all deserve an explanation as to the Aspire agreement, what happened with that AND the $12.45M they had in cash at year-end 2015. It was unexpected, and shares reacted accordingly. Let's hope shorts covered, otherwise greed will catch them later.
Friday was lousy again after a partial lift Thursday. This isn't going to my script just sayin'. I hate to acknowledge that the short trade here is alive and not to be ignored or taken for granted. Shorts on biotech stocks are the lowest form of life, but maybe they are a necessary evil to keep it real, without which there would be incessant pumping. I'm all for keeping it real, but Ganaxolone is going to rock in trials, so they will get their time in the sand pit soon enough and I will still be holding my shares long. RIP losers!
Jerry, I am new here in last few weeks but it's hard to temper one's enthusiasm, you are obviously a good guy with best intentions and you added value today by bringing this posted information forward. The story is big here, and it's happening and verifiable. Mark's comment above is appreciated in balance, we have to keep it real and also explore the challenges. Too much of only showing the prospective upside gets some people in over their head and we want a balanced presentation here. Adding today was a joy and with supreme confidence. Of 10 stocks I hold this was one of two green, and I was adding big time to make it so. GLAL.
I missed the early, on-sale shares, but managed to build a floor under our stock at 2.30 for most of the last 90 minutes. By adding 17,000 shares, I brought my average price down to 2.34. I think I'm set now, but always can jettison some other positions if this starts hitting a forward stride. What an interesting opportunity, to be here at this stage, just prior to the rocket launch. Very excited to hear what Gil and Company have prepared for us next week. Have a terrific weekend longs!
Expecting a different result will only drive you nuts (sic). $4.40 in December 2015, $1.66 today, the stock is down 62% since, in 4.5 months. Until the pipeline matures, and they come up with something in humans that impresses investors, and adheres to the value of their stock, the most you can expect is counter-trend 'pops' from time to time, that fade. The market remains bearish on biotech, especially early stage developmental small caps. Of course, there are exceptions, like CPXX. Is IDRA the next exception?
The commercialization stage is often fraught with risk and doubt, so how is it with a market that is slow to adopt new paradigms, that you remain so bullish? I am long and now down 20%, hope you are correct.
As did I am so far 237,400 shares have changed hands. I have an open order at 2.30 with partial fill now. I just can't see where this can go wrong with what we know now, and the upside is huge.
I emailed investor relations, will report here what I learn if I get a reply. They aren't answering calls to the main number and I didn't have another number or name. Disillusioned, upset with this action now, after being led to believe they had sufficient cash on hand $12.54M at 2015 year end, together with Aspire agreement for $15M. That's 27.54 million, what's up?
Thanks for clarifying. Time to buy more AVXL? GALE? Biggest loser is IDRA, my recent sells @ $1.99, 1.97, 1.95, 1.90, 1.85. Today's close $1.71! #$%$! It may test $1.50?
Stock trading down to 1.10 on low volume. Panic sellers, don't understand this capital is necessary for growing the company. I do question the need for it now however, as they have the stock purchase agreement in place with Aspire Capital, that should have given them the legs to have extended this well into next year had they used it. Maybe they didn't like the terms of that agreement? Anyone here have insight?
You expect positive results in this instance, yet your earlier post I replied to "on a positive note" reads otherwise?